Objective: to assess the status of lipidsoluble antioxidants (carotenoids, tocopherols, ubiquinone), retinol and their correlation with TRAP (total radical-trapping antioxidant potential) in patients with Crohn's disease. Design: Prospective case-control study. Setting: Clinic of Internal Medicine IVaDepartment of Gastroenterology and Hepatology, University of Vienna Medical School. SubjectsaMethods: Plasma antioxidant concentrations were determined in patients with Crohn's disease n 24 to evaluate the antioxidant capacity compared to healthy controls n 33. Additionally, plasma TRAP (total radical-trapping anitoxidant potential) was measured in 13 patients and 22 controls. Results: All investigated carotenoids (-carotene, -carotene and cryptoxanthin) were signi®cantly decreased in patients with Crohn's disease (10X2 AE 9X3, 16X2 AE 12X4 and 7X8 AE 5X5 mgadl) compared to controls (13X3 AE 5Y 1, 34X7 AE 18X8 and 48X5 AE 38X4 mgadl, respectively), whereas g-tocopherol and ubiquinone were signi®-cantly elevated in patients (0X14 AE 0X07 mgadl and 82X3 AE 41X5 mgadl, controls: 0X09 AE 0X04 mgadl and 60X8 AE 30X0 mgadl, respectively). Retinol and -tocopherol did not signi®cantly differ from controls. The total radical-trapping antioxidant potential (TRAP) was signi®cantly lower in patients (1X11 AE 0X28 mmolal) compared to controls (1X34 AE 0X26 mmolal). Antioxidants were neither related to duration or severity of disease nor to disease activity. Conclusions: In patients with Crohn's disease several plasma antioxidant parameters are altered and the total radical-trapping antioxidant potential is decreased.
Introduction
Crohn's disease is an in¯ammatory bowel disease of unknown etiology, mainly affecting the small intestine and the colon. Pathogenetic concepts include genetic predisposition, immunological abnormalities, and environmental factors, such as infectious agents, smoking, and dietary factors (MacDermott, 1997) .
The intestinal in¯ammation is histologically characterized by an in®ltration of polymorphonuclear leukocytes and monocyte-macrophages. They are activated by various mediators including prostaglandins, leucotriens, platelet activating factor and cytokines to synthesize and release reactive oxygen metabolites (Simmonds & Rampton, 1993; Lih-Brody et al, 1996) . A positive correlation between the activity of free radicals (y À P , r P y P , yr) in the intestine and the clinical disease activity has been demonstrated indicating the importance of these substances in the in¯am-matory process (Nielsen & Ahnfelt-Rùnne, 1991) .
Enzymatic and nonenzymatic systems exist for limiting the damage of toxic oxygen metabolites. However, even under normal physiological conditions, enzyme activities of catalase, superoxide dismutase and glutathione peroxidase are relatively low in the intestinal mucosa compared to other tissues (Grisham et al, 1990) . In the in¯amed mucosa of patients with Crohn's disease decreased antioxidant capacities have been described as demonstrated by lower total peroxyl radical scavenging capacity and lower contents of urate, ubiquinol-10 and ascorbic acid (Buf®nton & Doe, 1995 a, b) .
Also, general malnutrition and speci®c abnormalities of vitamins, minerals and trace elements in the blood of Crohn's disease patients have been described (Kelly & Fleming, 1995; Geerling et al, 1998) . Especially low blood values of the lipid-soluble vitamins A (FernandezBanares et al, 1989 , Kuroki et al, 1993 Bousvaros et al, 1998) and D (Vogelsang et al, 1994) and of the watersoluble vitamins folic acid and Vitamin f IP were reported (Kuroki et al, 1993) . Contradictory results exist for tocopherols in these patients (Ferandez-Banares et al, 1989 , Kuroki et al, 1993 , Hoffenberg et al, 1997 , Geerling et al, 1998 . The status of carotenoids in combination with other anitoxidants has only rarely been described in detail in adult patients with Crohn's disease.
We investigated the status of carotenoids (a-carotene, bcarotene and cryptoxanthin), retinol, a-and g-tocopherol and ubiquinone in patients with Crohn's disease. Furthermore, we determined the plasma total radical-trapping *Correspondence: I Elmadfa, Institute of Nutritional Sciences, University of Vienna, Austria. {Guarantor: I Elmadfa Contributorship: D Genser collected the clinical data and drafted the manuscript. M-H Kang did the statistical analysis and helped with the preparation of the manuscript. H Vogelsang supervised the clincal part of the study. I Elmadfa was involved in the study design and supervised the laboratory work. All authors were involved in the revision of the manuscript.
antioxidant potential (TRAP), a measure for the combined activity of antioxidants to resist controlled in-vitro peroxidation.
Subjects and Methods

Subjects
We investigated 24 (10 males, 14 females) patients with Crohn's disease visiting the outpatient clinic for in¯amma-tory bowel disease. Diagnosis was based on standard clinical, radiological, endoscopic and histological criteria according to Malchow et al (1984) . 33 healthy volunteers (13 males, 20 females) were used as controls. Informed consent was given before blood was drawn into a lithiumheparinized polystyrene tube. Plasma was separated by centrifugation at 3000 rpm for 30 min and stored at À80 g until analysis.
Clinical parameters
The following clinical parameters were evaluated ( 
Vitamins and antioxidants
Retinol, carotenes, cryptoxanthin, tocopherols and ubiquinone were determined by a reversed-phase HPLC method previously described in detail (Jakob and Elmadfa, 1995) . Brie¯y, after samples were thawed, plasma proteins were precipitated with ethanol and lipids were extracted with nhexane. After evaporation, residues were reconstituted with the eluent (dichloromethane and methanol, 15:85) and 150 ml were injected into a guard-column (Merck LiChrospher 100 RP-18, 250 Â 4X0 mm i.d., 5 mm). Samples were run at a¯ow rate of 0.8 mlamin. on a Merck Hitachi Pump L-7100 and detected on a Merck Hitachi UV Detector 7400 with an Integrator D-7500 (all from Merck, Germany). Absorption was monitored at 325 nm for retinol, at 295 nm for tocopherols, at 450 nm for carotenoids and at 270 nm for ubiquinone. Concentrations were calculated from areas under the curve using an external calibration curve. TRAP TRAP was analyzed using an inhibition assay described by Rice-Evans & Miller (1994) . This method is based on the measurement of the absorbance of the radical cation of ABTS (2,2 H -azinobis(3-ethylbenzothiazoline 6-sulfonate)), which is formed by the interaction of ATBS (150 mM ®nal concentrationa400 ml) with ferrylmyoglobin radical species. The latter are generated by activation of metmyoglobin (2.5 mMa2ml) with r P y P (75 mMa170 ml) at 30 g. The suppression of the absorbance is proportional to the antioxidant capacity of the samples (0.84% plasma; PBS buffer, pH 7.4 to make 1.0 ml). Absorbance was measured at 734 nm after 6 min. of incubation on a UVaVIS Spectrometer Lambda 2 (Perkin Elmer, Germany). Values are expressed as TEAC (Trolox equivalent antioxidant capacity), de®ned as the millimolar concentration of the Trolox anitoxidant capacity of a calibration curve.
In¯ammation parameters C-reactive protein (CRP, normal range:`1Y 0 mgadl) and 1 -acid glycoprotein ( orosomucoid, normal range: 40-120 mgadl) were determined after immunoprecipitation by turbidimetry and nephelometry, respectively, on a Behring Nephelometer-Analyzer (Behring, Germany). Chemicals D,L--tocopherol was generously provided by Hoffman La Roche AG; D,L--tocopherol was purchased from Merck and cryptoxanthin from Hoffman La Roche AG. -carotene, -carotene, retinol, ubiquinone, myoglobin and ABTS (2,2 H -azinobis (3-ethylbenzothiazoline 6-sulfonate) were from Sigma, Trolox, methanol and n-hexane were purchased from Fluka, dichloromethane and ethanol were from Riedel-de-Haen, r P y P (30%) was from Donauchem.
Statistics
Differences between groups were calculated using the Mann-Whitney U test. Spearman's correlation coef®cient was used for calculating correlations.
Results
Clinical parameters
The majority of patients had low disease activity at the time of investigation (CDAI`150), which is con®rmed by low values of the in¯ammation parameters CRP and 1 -acid glycoprotein. However, disease severity (based on disease Lipidsoluble antixoidants and TRAP in Crohn's disease D Genser et al history and actual treatment) was quite heterogeneous (Table 1) .
Vitamins, antixodative parameters and TRAP Data for all investigated parameters are shown in Table 2 . Plasma carotenoids were highly signi®cantly lower in patients with Crohn's disease. -carotene was 23% lower in patients, the value for -carotene was only half and for cryptoxanthin only one sixth compared to the control group. In contrast, there was a trend for higher concentrations of retinol in patients with Crohn's disease P 0X095.
Mean values for -tocopherol were exactly the same in both groups, whereas -tocopherol was signi®cantly higher in patients. Mean plasma ubiquinone was signi®cantly higher (35%) in patients compared to controls.
Even though values for TRAP were only available in 13 patients, TRAP was signi®cantly decreased in patients with Crohn's disease compared to controls.
In¯uence of smoking status
Anlaysis was also performed according to the smoking status. 15 out of 24 patients and 15 out of 33 controls were current smokers. Neither within the patient nor within the control group were there any signi®cant differences between smokers and non-smokers (data not shown). In smokers as well as in non-smokers -carotene and cryptoxanthin were signi®cantly lower in patients compared to controls (Table 3 ). Probably also due to the smaller sample size there were no other signi®cant differences in nonsmokers, whereas in smokers retinol and -tocopherol were signi®cantly elevated and TRAP was signi®cantly decreased in patients.
Correlations between in¯ammation, antoxidative and clinical parameters in patients
There was a signi®cant correlation between 1 -acid glycoprotein and severity of disease (r 0.43, P`0.05). Correlations between antioxidants and in¯ammation parameters were not statistically signi®cant except for a negative correlation between -carotene and 1 -acid glycoprotein (r À0X45, P`0X05). As far as clinical parameters are concerned, the only signi®cant one was a negative correlation between duration of disease and retinol (r À0X43, P`0X05).
Discussion
There is increasing evidence for reactive oxygen metabolites to mediate tissue injury in chronic in¯ammatory bowel disease (Lih-Brody et al, 1996) . Since the intestine is especially vulnerable to oxidant injury due to low concentrations of endogeneous antioxidant enzymes (Grisham et al, 1990) , the status of antioxidants in those diseases is of practical interest. Because patients with Crohn's disease are especially prone to dietary de®cits, we investigated this group of patients.
In accordance with previous reports (Fernandez-Banares et al, 1989; Geerling et al, 1998) we found severely decreased mean levels of -carotene in plasma of patients with Crohn's disease compared to healthy controls. In contrast to these previous studies we additionally determined -carotene, which was also signi®cantly lower in patients, and cryptoxanthin, which was even more depleted in patients (1a6 of the control group). Thus, levels of three carotenoids were decreased in patients, indicating a substantial de®cit for this group of substances, which are well known for various antioxidative properties (Miller et all, 1996) .
For retinol, decreased levels of serum retinol binding protein have been suggested as a relevant factor for low blood values (Janczewska et al, 1991) . However, in contrast to several other studies (Fernandez-Banares et al, 1989; Kuroki et al, 1993; Bousvaros et al, 1998) , our patients did not show signi®cantly different values compared to controls, which is in accordance with the most recent study in Crohn's disease patients in remission (Geerling et al, 1998) . Whereas there was no correlation between disease activity and retinol, as also described previously (Scho Èlmerich et al, 1985) , we found a signi®- Table 3 Levels of antioxidants, retinol and TRAP in patients with Crohn's disease and controls by smoking status (meanAEstandard deviation)
Smokers n 30
Non-smokers n 27
Patients (n 15) Controls (n 15) Patients (n 9) Controls (n 18)
* P`0X05, ** P`0X01 and *** P`0X001, signi®cant difference between patients and controls by Mann-Whitney U Test. a n 8 and 14 for patients and controls in smokers, and n 5 and 15 for patients and controls in non-smokers, respectively. b n 8 and 10 for patients and controls in smokers, and n 5 and 12 for patients and controls in non-smokers, respectively. 
* P`0X05,** P`0X01 and *** P`0X001, signi®cant difference between patients and controls by Mann-Whitney U Test. a n 13 for the patient group and n 29 for the control group. b TRAP Total radical-trapping antioxidant potential; n 13 for the patient group and n 22 for the control group.
Lipidsoluble antixoidants and TRAP in Crohn's disease D Genser et al cant negative correlation between retinol and the duration of disease, which could indicate that patients with long disease history are at higher risk for low retinol levels. Whereas most studies report low blood levels of vitamin D (Vogelsang et al, 1994) in patients with Crohn's disease, data are less clear for tocopherols. Signi®cantly decreased concentrations of -tocopherol have been described (Kuroki et al, 1993; Bousvaros et al, 1998 , Geerling et al, 1998 , as well as signi®cantly higher values (Hoffenberg et al, 1997) , but also similar values compared to controls (Fernandez-Banares et al, 1989 , Kuroki et al, 1994 . -tocopherol has not been investigated in adult patients with Crohn's disease so far. We found no difference intocpherol levels between patients and controls, whereas -tocopherol was sign®cantly increased in the patient group. This ®nding is of special interest, since -tocopherol is more effective than -tocopherol in trapping peroxinitrite and other reactive nitrogen oxide species (Wolf, 1997) . In Crohn's disease patients increased nitric oxide production in the in¯amed mucosa together with elevated plasma nitric oxide concentrations have recently been reported (Kimura et al, 1997) . The mechanism for the elevation oftocopherol is unclear. However, increased values oftocopherol in experimentally induced in¯ammatory conditions have been reported earlier, such as in rats treated with Freud's complete adjuvants (Sobirey et al, 1986) and in rabbits receiving turpentine subcutaneously (Proulx et al, 1995) .
To our knowledge, this is the ®rst study to describe ubiquinone in plasma of patients with Crohn's disease. In addition to its function as component of the mitochondrial electron transfer chain, ubiquinone in its reduced form can also serve as an antioxidant. It is the only known lipidsoluble antioxidant that can be synthesized endogeneously (Ernster & Dallner, 1995) . Ubiquinone was signi®cantly increased in our patients compared to controls, which is in accordance with the ®nding that the production of ubiquinone is stimulated under the in¯uence of oxidative stress (Ernster & Dallner, 1995) . The concentration of ubiquinone was also found to be higher in the in¯amed mucosa of Crohn's disease patients compared to the adjacent nonin¯amed mucosa (Buf®nton & Doe, 1995b) . Therefore, the increased values of ubiquinone in patients can be regarded as a response in order to prevent free-radical damage induced by the in¯ammation.
To sum up, levels of antioxidants in patients with Crohn's disease are partly different from healthy controls. The carotenoids -carotene, -carotene and cryptoxanthin are signi®cantly decreased in patients. Retinol andtocopherol are unchanged, whereas -tocopherol and ubiquinone are signi®cantly elevated. These differentiated results make it dif®cult to rely on the measurement of few substances for evaluation of the antioxidative status of patients with Crohn's disease. Therefore, a functional test representing the overall antioxidative capacity would be useful. The total radical-trapping antioxidant potential (TRAP) as determined in this study may ful®ll this requirement. It was signi®cantly lower in our patients with Crohn's disease, as indicated by the sign®cantly decreased value for the total radical-trapping antioxidant potential (TRAP).
Reactive oxygen metabolites are not only involved in the in¯ammation process, but also in chromosomal damage (Lee et al, 1990) . We have recently shown increased chromosome instability in our patients with Crohn's disease demonstrated by increased sister chromatid exchanges in periphal blood lymphocytes (Kang et al, 1997) . The resulting increased risk for mutagenesis and cancer could possibly be lowered by improving the status of antioxidants. A positive clinical effect of the treatment with the antioxidative enzyme copper zinc superoxide dismutase in patients with severe Crohn's disease has been described (Emerit et al, 1991) . It may be worthwhile to undertake clinical studies with supplementation of antioxidative vitamins in order to suppress the in¯ammatory process induced by reactive oxygen and nitrogen species, as requested again recently (Jeejeebhoy, 1998) . However, special care has to be taken in designing such trials, since the possible hazard of supplementing only single substances in pharmacological doses is demonstrated by the adverse outcome of recent trials with -carotene, which resulted in an increase of lung cancer in risk populations (for example Albanes et al, 1995) .
Our results emphasize the importance of measuring several antioxidative parameters and not to rely on single parameters for evaluating the antioxidative potential. An alternative may be the determination of TRAP, a functional test, which represents the combined activity of several antioxidants.
